Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,105 across all filing types
Latest filing 2022-03-21 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Director's Dealing 2022
Director's Dealing
2022-03-21 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Supplement to the 2022 Notice of Annual Meeting and Proxy Statement for Johnson & Johnson's Annual Meeting of Shareholders. It specifically updates information about the withdrawal of a shareholder proposal and clarifies voting instructions. The document is titled as a 'Supplement' and references the Proxy Statement, indicating it is additional material related to the proxy solicitation process. It is not the main Proxy Statement itself, nor is it a report of voting results or a full annual report. Given the nature of the content—updates and additional information related to the proxy materials—the appropriate classification is 'DEF 14A' which covers remuneration and proxy solicitation related materials, including supplements to proxy statements. The document length and content confirm it is not a brief announcement or a full report but a definitive additional material to the proxy statement.
2022-03-17 English
Director's Dealing 2022
Director's Dealing
2022-03-17 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a Notice of Exempt Solicitation filed on SEC Form PX14A6G, which is used for shareholder communications related to proxy solicitations but exempt from certain filing requirements. The text is a shareholder rebuttal urging a vote FOR a shareholder proposal (Item 9) related to Johnson & Johnson's intellectual property rights on COVID-19 vaccines. It discusses the proposal's background, rationale, and arguments for supporting the proposal. The document does not contain financial statements, earnings data, or management discussion of results. It is not a proxy statement itself but a solicitation communication related to a proxy vote. The document is lengthy (15,000 characters) and substantive but is not a report or financial filing like an Annual Report or Proxy Solicitation Statement. It is a shareholder communication filed under SEC rules for exempt solicitations. This type of document fits best under Regulatory Filings (RNS) as a general regulatory announcement and shareholder communication that does not fit other categories like Proxy Solicitation & Information Statement (PSI) because it is not the official proxy statement but a solicitation communication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-03-16 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A INFORMATION' and is identified as a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is filed by Johnson & Johnson and is marked as 'Definitive Additional Materials.' The Schedule 14A is a proxy statement used to provide information to shareholders to solicit their votes for corporate matters, typically related to board elections, executive compensation, or other governance issues. The document is not a full annual report, earnings release, or other financial report but rather materials related to shareholder voting and governance. According to the filing definitions, proxy solicitation and information statements fall under the category 'Proxy Solicitation & Information Statement' with code PSI. The document length is 1943 characters, which is consistent with a proxy statement or related materials rather than a full report. Therefore, the correct classification is PSI.
2022-03-16 English
DEF 14A
Proxy Solicitation & Information Statement
2022-03-16 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.